soul trial oral semaglutide cardiovascular outcomes 2025 results Abstract 4351008: Comparing in New Users of Versus Other Noninsulin Glucose-Lowering Therapies New in the May 29,

Ecnoglutide may offer a competitive alternative in certain markets, particularly China, but its biased signaling advantage has not yet been demonstrated in head-to-head comparison with semaglutide

Resistenztraining, ergnzt durch Ausdauer-, Balance- und Flexibilittsbungen zur Frderung von Funktionalitt und kardiovaskulrer Gesundheit und unter Bercksichtigung der individuellen Voraussetzungen der Patient/-innen zeitgleich zum Behandlungsbeginn mit einem GLP-1-RA (18, 51, 52)

Other GLP-1 Receptor Agonists These medications work similarly to Ozempic by mimicking a naturally occurring hormone (GLP-1) that helps reduce appetite and promote weight loss

After 10 years of treatment, the incidence of MALE was significantly lower in the GLP-1RAs group than in the non-GLP-1RAs group (Monfeuga et al., 2024)